-
Belimumab, sold
under the
brand name Benlysta, is a
human monoclonal antibody that
inhibits B-cell
activating factor (BAFF), also
known as B-lymphocyte...
- 'off-label'. In
November 2010, an FDA
advisory panel recommended approving belimumab (Benlysta) as a
treatment for the pain and flare-ups
common in lupus....
- and CEO.
Benlysta (
belimumab)
received U.S. Food and
Regulatory Administration approval for use in
lupus in
March 2011.
Belimumab was
being developed...
-
first new drug for
lupus in more than 50
years to be used in the US,
belimumab. In
addition to
medical therapy,
cognitive behavioral therapy has also...
- mycophenolate, cyclophosphamide, low dose IL-2,
intravenous immunoglobulins, and
belimumab.
Omalizumab is a
monoclonal antibody that
interacts with the
binding site...
- US$3 billion; the
companies had
collaborated on
developing the
lupus drug
Belimumab (Benlysta),
albiglutide for type 2 diabetes, and
darapladib for atherosclerosis...
- and neuropathy,
biologic immunosuppressant drugs such as
rituximab and
belimumab that work via B-cell
pathology are
often used and have less
toxic profiles...
-
predominantly on the
surface of B cells. Like the
monoclonal antibody belimumab,
atacicept blocks the
binding of BLyS, but it also
blocks APRIL. Binding...
-
Bactroban (mupirocin)
Becotide (beclomethasone dipropionate)
Benlysta (
belimumab)
Betnovate (betamethasone valerate)
Blenrep (belantamab mafodotin) Blujepa...
- L04AG01 Muromonab-CD3 L04AG02
Efalizumab L04AG03
Natalizumab L04AG04
Belimumab L04AG05
Vedolizumab L04AG06
Alemtuzumab L04AG07
Begelomab L04AG08 Ocrelizumab...
